Pregestasyonel Diyabet ve Fetal Programlama

Pregestasyonel diyabetli gebelerde maternal, fetal ve neonatal komplikasyonların ortaya çıkma riski artmaktadır. İntrauterin çevre; gen ekspresyonundaki değişiklikler, oksidatif stres ve epigenetik modifikasyon gibi yolaklar üzerinden fetal programlanmaya katkıda bulunur. Özellikle fetüsün maternal dönemde hiperglisemi ile karşılaşmış olması intrauterin çevresi için endişe verici bir konudur. Bu nedenle hiperglisemi riski olan bireylerde, gebelik öncesi dönemde glisemik kontrol sağlanana kadar aile planlaması yapılmalıdır. Gestasyonel dönemde ise fetal riskleri ve gebelik komplikasyonlarını en aza indirgeyebilmek için ortalama kan glukoz düzeyi 100 mg/dL (5.6 mmol/L) ve HbA1c değeri

Pregestational Diabetes and Fetal Programming

The risk of maternal, fetal and neonatal complications increase in pregnant women with pregestational diabetes. The intrauterine environment contributes to fetal programming from pathways such as changes in gene expression, oxidative stress and epigenetic modification. Fetus facing hyperglycemia during maternal period is a challenging factor for intrauterine environment. Therefore, family planning should be done in individuals with hyperglycemia risk, until glycemic control is achieved in the prenatal period. In the gestational period, the average blood glucose level should be maintained at 100 mg/dL (5.6 mmol/L) and HbA1c

Kaynakça

1. International Diabetes Federation. Diabetes Atlas. 9th ed. 2019. Available at: https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf Accessed: 20.06.2020

2. Öztürk Ünsal İ, Çakal E. Pregestasyonel diyabet. In: Çakal E, editor. Gebelik ve diyabet 1. Baskı. ed. Ankara: Türkiye Klinikleri; 2020. p. 14-8.

3. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol. 2018;132(6):e228-e48.

4. Shub A, Lappas M. Pregestational diabetes in pregnancy: Complications, management, surveillance, and mechanisms of disease-A review. Prenat Diagn. 2020.

5. Egan AM, McVicker L, Heerey A, Carmody L, Harney F, Dunne FP. Diabetic retinopathy in pregnancy: A population-based study of women with pregestational diabetes. J Diabetes Res. 2015;2015:310239.

6. Temple RC, Aldridge VA, Sampson MJ, Greenwood RH, Heyburn PJ, Glenn A. Impact of pregnancy on the progression of diabetic retinopathy in Type 1 diabetes. Diabet Med. 2001;18(7):573-7.

7. Kelly CB, Hookham MB, Yu JY, Jenkins AJ, Nankervis AJ, Hanssen KF, et al. Subclinical first trimester renal abnormalities are associated with preeclampsia in normoalbuminuric women with type 1 diabetes. Diabetes Care. 2018;41(1):120-7.

8. Tsakiridis I, Mamopoulos A, Athanasiadis A, Kourtis A, Dagklis T. Management of pregestational diabetes mellitus: A comparison of guidelines. J Matern Fetal Neonatal Med. 2020:1-10.

9. Sweeting AN, Ross GP, Hyett J, Molyneaux L, Constantino M, Harding AJ, et al. Gestational diabetes mellitus in early pregnancy: Evidence for poor pregnancy outcomes despite treatment. Diabetes Care. 2016;39(1):75-81

10. Mackin ST, Nelson SM, Kerssens JJ, Wood R, Wild S, Colhoun HM, et al. Diabetes and pregnancy: National trends over a 15 year period. Diabetologia. 2018;61(5):1081-8.

11. Battarbee AN, Venkatesh KK, Aliaga S, Boggess KA. The association of pregestational and gestational diabetes with severe neonatal morbidity and mortality. J Perinatol. 2020;40(2):232-9.

12. Lock MC, Botting KJ, Tellam RL, Brooks D, Morrison JL. Adverse intrauterine environment and cardiac mirna expression. Int J Mol Sci. 2017;18(12).

13. Chen P, Piaggi P, Traurig M, Bogardus C, Knowler WC, Baier LJ, et al. Differential methylation of genes in individuals exposed to maternal diabetes in utero. Diabetologia. 2017;60(4):645-55.

14. Wang X, Lu J, Xie W, Lu X, Liang Y, Li M, et al. Maternal diabetes induces autism-like behavior by hyperglycemia-mediated persistent oxidative stress and suppression of superoxide dismutase 2. Proc Natl Acad Sci U S A. 2019;116(47):23743-52.

15. Türkiye Endokrinoloji ve Metabolizma Derneği (TEMD) Diabetes Mellitus Çalışma ve Eğitim Grubu. Diabetes Mellitus ve Komplikasyonlarının Tanı, Tedavi ve İzlem Kılavuzu. Ankara: Bayt Matbaası; Nisan 2019.

16. American Diabetes Association. 14. Management of diabetes in pregnancy: Standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S183-S92.

17. National Institute for Health and Care Excellence: Clinical Guidelines. Diabetes in pregnancy: management from preconception to the postnatal period. London: National Institute for Health and Care Excellence (UK).

18. Nielsen LR, Ekbom P, Damm P, Glümer C, Frandsen MM, Jensen DM, et al. HbA1c levels are significantly lower in early and late pregnancy. Diabetes Care 2004;27(5):1200- 1.

19. Köksal G, Gökmen Özel H. Çocuk Hastalıklarında Beslenme Tedavisi. Ankara: Hatiboğlu Yayınevi; 2019. s. 39-326

20. Di Biase N, Balducci S, Lencioni C, Bertolotto A, Tumminia A, Dodesini AR, et al. Review of general suggestions on physical activity to prevent and treat gestational and pre existing diabetes during pregnancy and in postpartum. Nutr Metab Cardiovasc Dis. 2019;29(2):115-26.

21. Diyabet Diyetisyenliği Derneği. Diyabetin Önlenmesi ve Tedavisinde Kanıta Dayalı Beslenme Rehberi-2019. İstanbul; 2019.

22. Institute of Medicine. Weight gain during pregnancy: Reexamining the guidelines. Washington, DC: National Academies Press; 2009.

23. Berry DC, Boggess K, Johnson QB. Management of pregnant women with type 2 diabetes mellitus and the consequences of fetal programming in their offspring. Curr Diab Rep. 2016;16(5):36.

24. Kwon E, Kim YJ. What is fetal programming?: A lifetime health is under the control of in utero health. Obstet Gynecol Sci. 2017;60(6):506-19.

25. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: The thrifty phenotype hypothesis. Diabetologia. 1992;35(7):595-601.26.

26. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced fetal growth. Diabetologia. 1993;36(1):62-7.

27. Finer S. Fetal programming via maternal diabetes: The controversy continues. Diabet Med. 2015;32(3):291-4.

28. Hiden U, Desoye G. The Placenta in a diabetic pregnancy. J Reproduktionsmed Endokrinol. 2010;7 (1): 27-33.

29. Singh R, Pearson E, Avery PJ, McCarthy MI, Levy JC, Hitman GA, et al. Reduced beta cell function in offspring of mothers with young-onset type 2 diabetes. Diabetologia. 2006;49(8):1876-80.

30. Aberg A, Westbom L, Källén B. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev. 2001;61(2):85- 95.

31. Avci R, Whittington JR, Blossom SJ, Escalona-Vargas D, Siegel ER, Preissl HT, et al. Studying the effect of maternal pregestational diabetes on fetal neurodevelopment using magnetoencephalography. Clin EEG Neurosci. 2020:1550059420909658.

32. Lindsay RS, Nelson SM, Walker JD, Greene SA, Milne G, Sattar N, et al. Programming of adiposity in offspring of mothers with type 1 diabetes at age 7 years. Diabetes Care. 2010;33(5):1080-5.

33. Russell NE, Higgins MF, Kinsley BF, Foley ME, McAuliffe FM. Heart rate variability in neonates of type 1 diabetic pregnancy. Early Hum Dev. 2016;92:51-5.

34. Knorr S, Bytoft B, Lohse Z, Boisen AB, Clausen TD, Jensen RB, et al. Fatty liver among adolescent offspring of women with type 1 diabetes (the EPICOM Study). Diabetes Care. 2019;42(8):1560-8.

Kaynak Göster